- Home
- PEPG vs AGEN Comparison
PEPG vs AGEN Comparison
Compare PEPG & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PEPG
- AGEN
- Stock Information
- Founded
- PEPG 2018
- AGEN 1994
- Country
- PEPG United States
- AGEN United States
- Employees
- PEPG N/A
- AGEN N/A
- Industry
- PEPG Biotechnology: Pharmaceutical Preparations
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PEPG Health Care
- AGEN Health Care
- Exchange
- PEPG Nasdaq
- AGEN Nasdaq
- Market Cap
- PEPG 52.4M
- AGEN 52.6M
- IPO Year
- PEPG 2022
- AGEN 2000
- Fundamental
- Price
- PEPG $1.38
- AGEN $3.47
- Analyst Decision
- PEPG Buy
- AGEN Buy
- Analyst Count
- PEPG 3
- AGEN 4
- Target Price
- PEPG $9.67
- AGEN $8.33
- AVG Volume (30 Days)
- PEPG 228.0K
- AGEN 1.0M
- Earning Date
- PEPG 05-08-2025
- AGEN 05-12-2025
- Dividend Yield
- PEPG N/A
- AGEN N/A
- EPS Growth
- PEPG N/A
- AGEN N/A
- EPS
- PEPG N/A
- AGEN N/A
- Revenue
- PEPG N/A
- AGEN $99,524,000.00
- Revenue This Year
- PEPG N/A
- AGEN $14.67
- Revenue Next Year
- PEPG N/A
- AGEN N/A
- P/E Ratio
- PEPG N/A
- AGEN N/A
- Revenue Growth
- PEPG N/A
- AGEN N/A
- 52 Week Low
- PEPG $0.88
- AGEN $1.38
- 52 Week High
- PEPG $19.30
- AGEN $19.69
- Technical
- Relative Strength Index (RSI)
- PEPG 46.11
- AGEN 67.96
- Support Level
- PEPG $1.46
- AGEN $2.83
- Resistance Level
- PEPG $1.66
- AGEN $4.06
- Average True Range (ATR)
- PEPG 0.17
- AGEN 0.34
- MACD
- PEPG 0.01
- AGEN 0.04
- Stochastic Oscillator
- PEPG 43.40
- AGEN 58.74
About PEPG PepGen Inc.
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle and the central nervous system. Its pipeline products are; PGN-EDO51, PGN-EDODM1, and others including PGN-EDO53 and PGN-EDO45.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).